New drug duo aims to outsmart stomach cancer
NCT ID NCT06346197
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a combination of two immunotherapy drugs (botensilimab and balstilimab) can help people with advanced stomach cancer live longer compared to standard treatment. The study includes 132 adults whose tumors have a specific genetic marker (MSI-H/dMMR). Participants will receive either the new drug combo or standard chemo plus another immunotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
botensilimab and balstilimab (immunotherapy drugs)
What this could lead to
If successful, this could offer a new treatment option for people with advanced stomach cancer that has specific genetic features.
What could go wrong
This is an early-stage Phase 3 trial with only 132 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Brest
RECRUITINGBrest, 29000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Clermont-Ferrand
RECRUITINGClermont-Ferrand, 63000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Poitiers
RECRUITINGPoitiers, 86000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Léon Bérard
RECRUITINGLyon, 69008, France
Contact Email: •••••@•••••
-
Hôpital Privé Jean Mermoz
RECRUITINGLyon, 69008, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Mutualiste Montsouris
RECRUITINGParis, 75000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Paoli Calmettes
RECRUITINGMarseille, 13000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••